|
MARKETWATCH
Drug Company–Sponsored Patient Assistance Programs: A Viable Safety Net?
Niteesh K. Choudhry,
Joy L. Lee,
Jessica Agnew-Blais,
Colleen Corcoran and
William H. Shrank
Drug company–sponsored patient assistance programs (PAPs) provide access to brand-name medications at little or no cost and have been advocated as a safety net for inadequately insured patients. Yet little is known about these programs. We surveyed drug company–sponsored PAPs and found much variability in their structures and application processes. Most cover one or two drugs. Only 4 percent disclosed how many patients they had directly helped, and half would not disclose their income eligibility criteria. A better understanding of PAPs might clarify their role in improving access to medications, the adequacy of existing public programs, and their impact on cost-effective medication use.

What's this?
This article has been cited by other articles:

|
 |

|
 |
 
K. Johnson
Voluntary Patient Assistance Programs: Additional Federal Oversight Unwarranted
Health Aff.,
May 1, 2009;
28(3):
835 - 838.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Weinberg
Reforming Patient Assistance Programs: Perfect World Meets Real World
Health Aff.,
May 1, 2009;
28(3):
839 - 842.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|